

## Perioperative Management of the Hemodialysis Patient

Dominic Trainor,\* Emma Borthwick,† and Andrew Ferguson\*

\*Department of Anaesthetics and Intensive Care Medicine, Craigavon Area Hospital, Portadown, United Kingdom, and †Department of Nephrology, Belfast City Hospital, Belfast, United Kingdom

### ABSTRACT

Dialysis-dependent chronic kidney disease (CKD) is an expanding problem for healthcare systems worldwide. The prevalence of end-stage renal disease (ESRD) has increased by 20% since 2000 and stands at 1699 per million people in the USA. ESRD is associated with an increased risk of cardiovascular comorbidity, increased severity of cardiovascular disease, and an adjusted all-cause mortality rate that is 6.4–7.8-fold higher than the general population. These patients may present electively or emergently for surgery related to, or remote from, the CKD. In any perioperative setting, the patient with hemodialysis-dependent CKD represents a significant clinical challenge, and successful management of these patients requires effective cooperation and communication between nephrology, anesthesia, and surgical staff. The ESRD patient's nephrologist will have the best knowledge of

their medical history, comorbidities, and future management goals and may have been the clinician who instigated the referral for the surgery, e.g., for parathyroidectomy, vascular access surgery, nephrectomy or renal transplantation. As such, they are in an ideal position to contribute to, or coordinate, early preoperative medical optimization of the patient and also to provide advice during postoperative recovery and rehabilitation. In this article, we provide an overview of some of the key aspects of managing these patients successfully during the perioperative period. We propose the integration of cardiopulmonary exercise testing and cardiovascular optimization into the care of these high-risk patients and provide an overview of the importance of maintaining microvascular perfusion and the role of viscosity in preserving the capillary perfusion network.

Dialysis-dependent chronic kidney disease (CKD) is an expanding problem for healthcare systems worldwide. The prevalence of end-stage renal disease (ESRD) has increased by 20% since 2000 and stands at 1699 per million people in the USA (1). ESRD is associated with an increased risk of cardiovascular comorbidity, increased severity of cardiovascular disease (2), and an adjusted all-cause mortality rate that is 6.4–7.8-fold higher than the general population (1). These patients may present electively or emergently for surgery related to, or remote from, the CKD. CKD is an independent risk factor for postoperative death and cardiac events (3), and successful perioperative management requires effective cooperation and communication between nephrology, anesthesia, and surgical staff. In this article, we provide an overview of some of the key aspects of managing these patients successfully during the perioperative period. We attempt to take the reader beyond the basic considerations to stimulate discussion around the integration of cardiopulmonary exercise testing (CPET) and cardiovascular optimization into the care of these high-risk patients and to provide an overview of the

importance of microvascular perfusion, particularly the role of blood and plasma viscosity in preserving the capillary perfusion network.

### Preoperative Medical Optimization of the Dialysis Patient

End-stage renal disease is a multisystem disorder. Cardiovascular disease remains the most frequent cause of death in patients with ESRD, the largest single cause being fatal arrhythmias. The high rate of associated multisystem comorbidity (Table 1) and the clinical effects of ESRD mandate a careful and systematic approach to preoperative preparation. The main features of such an approach are included in the following:

### Dialytic Correction of Metabolic Status

Hemodialysis (HD) adequacy is extremely important in the perioperative period and cannot be assumed simply from the patient's biochemical results, e.g., blood urea and creatinine levels, or by relying on the absence of uremic symptoms. Dialysis dose can be determined using estimation of the volume of blood cleared during a treatment, the so-called  $Kt/V$ . National and international standards exist (5) to define the target values for these measures, for example a minimum adequate treatment  $Kt/V$  of 1.2 for three times weekly dialysis, with a target dose of 1.4 per dialysis. It remains unclear whether

*Address correspondence to:* Andrew Ferguson, Consultant, Department of Anaesthetics and Intensive Care Medicine, Craigavon Area Hospital, 68 Lurgan Road, Portadown BT63 5QQ, United Kingdom, Tel.: +44-2838-612307, Fax: +44-2838-868565, or e-mail: a\_ferguson@me.com.

*Seminars in Dialysis*—Vol 24, No 3 (May–June) 2011 pp. 314–326

DOI: 10.1111/j.1525-139X.2011.00856.x

© 2011 Wiley Periodicals, Inc.

**TABLE 1. Comorbid conditions in incident HD dialysis patients starting dialysis between 2003 and 2008**

Comorbidity	Number	Percentage (%)	Median age (years)
Angina	1845	16.9	71.3
MI in past 3 months	339	3.1	70.7
MI > 3 months ago	1304	11.9	70.8
CABG/angioplasty	837	7.7	69.0
Cerebrovascular disease	1,177	10.8	71.1
Diabetes (not listed as PRD)	977	9.1	70.9
COPD	855	7.9	70.8
Liver disease	329	3.0	60.0
Claudication	957	8.7	70.6
Ischemic/neuropathic ulcers	410	3.7	62.6
Angioplasty/vascular graft	411	3.8	71.4
Amputation	248	2.3	61.3
Smoking	1629	15.3	61.2
Malignancy	1457	13.3	72.0

Modified from (4).

achieving dialysis adequacy above the normal target levels (i.e., more intensive dialysis) improves surgical outcomes. It should be noted that dialysis dosing is based on fractional removal of toxins, regardless of any (largely unmeasurable) differences in their rate of production. The latter may well be increased in the often catabolic perioperative setting.

### Management of Anemia

Loss of erythropoietin secretion as CKD progresses is the major factor that results in anemia in the vast majority of patients with HD-dependent ESRD if they remain untreated. This diminishes aerobic capacity and quality of life (6), as well as potentially aggravating myocardial dysfunction in susceptible individuals. Therapy with iron supplementation (e.g., intravenous iron) and erythropoietic-stimulating agents (ESAs) currently target a hemoglobin concentration of between 11 and 12 g/dl (hematocrit 33–36%) (7). If reduction in the need for perioperative transfusion is desired, this target can be increased preoperatively by careful titration of ESA dose, although this will take a number of weeks to achieve. It should also be noted that there are concerns over adverse outcomes when using higher ESA doses to achieve hemoglobin levels above the aforementioned targets on a longer-term basis (8). The ESA dose may also need to be increased postoperatively to allow correction of surgery-induced anemia and to overcome the generated inflammatory response, which induces erythropoietin resistance. In this setting, iron repletion should also be optimized to facilitate the response.

### Tailoring of Blood Pressure and Heart Failure Treatment

Hypertension is common in HD patients, and good control should be achieved to minimize perioperative instability. Management will include achieving the correct dry weight with optimization of fluid removal, adjusting the dose of antihypertensive drugs, or adding additional agents. Intradialytic or postural hypotension is another common issue in HD patients, contributed to

by excessive or too rapid fluid removal on dialysis, myocardial dysfunction, aggressive antihypertensive regimens, infection, pericardial effusion, exaggerated peripheral vasodilatation (worsened by anemia) and abnormal sympathetic function (e.g., autonomic neuropathy). The cause should be sought and treated where possible (e.g., midodrine for intradialytic hypotension). Diastolic hypotension is an under-appreciated contributor to adverse cardiovascular outcomes (9).

Heart failure medication should be tailored to optimum effect in the weeks before surgery with decisions regarding drug administration during the immediate preoperative period made in consultation with the anesthesiologist or, if available, using agreed local protocols. In general, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are omitted on the day of surgery because of the risk of significant hypotension at induction of anesthesia.

### Blood Glucose Control

In the diabetic patient, therapeutic regimens should be tailored for best control of blood glucose, while also minimizing the risks of hypoglycemia. During the perioperative phase, hospital protocols or an individualized management plan should be used to ensure safe glucose levels, generally considered to be target levels < 180 mg/dl or 10 mmol/L (10,11). This may necessitate early involvement of specialist diabetic services. The targeting of much tighter glucose control is associated with increased risk of hypoglycemia and adverse events and is not currently justified (12). Hypoglycemia is a particular risk in this setting in patients treated with glyburide, an agent best avoided in dialysis patients.

Patients who have not been formally diagnosed with diabetes should also be assessed for hyperglycemia, because surgical stress may unmask and aggravate glucose handling problems in those with non-insulin dependent diabetes and also lesser degrees of glucose intolerance. Dialysis patients are also at increased risk of hypoglycemia with fasting.

### Calcium, Phosphate and Parathyroid Hormone Management

Disorders of mineral metabolism are universal in patients with ESRD and include reductions in vitamin D and elevations in phosphate and parathyroid hormone. These abnormalities are associated with increased mortality risk, although it is unclear whether they are causative or whether treatment results in reduction of this risk (13). Medical management includes the use of phosphate binders and vitamin D analogs, although achieving recommended treatment targets is difficult (14).

Rates of parathyroidectomy have increased again from 2005 through to 2007 after a previous decline (15). The so-called hungry bone syndrome affects between 13% and 30% of parathyroidectomy patients. It consists of significant, symptomatic (tetany or seizures), and often prolonged hypocalcaemia, most often in patients with pre-existing bone disease and chronically raised

bone reabsorption rates. In patients undergoing parathyroid/thyroid surgery with significant parathyroid hormone levels (typically >800 pg/ml), the nephrologist may choose to prescribe high doses of calcitriol in the week running up to surgery to reduce the risk of this complication. Postoperative calcium and phosphate levels should be closely monitored. Hyperkalemia is not uncommon in dialysis patients postparathyroidectomy, occurring in 80% of patients in one series (16), although the mechanism is not understood.

### Fluid and Electrolyte Status

Close attention should be paid to establishing the correct “dry weight” for the patient, i.e., the weight at which they are euvolemic. If the patient is above their dry weight preoperatively, they risk pulmonary edema and poorly controlled hypertension perioperatively and poor tissue healing postoperatively. If under their dry weight, they may become profoundly hypotensive during anesthesia, which will be exacerbated by blood loss. It is usual to target low normal potassium levels going into surgery. Blood sampling in the very early postdialysis period may return very low serum potassium values; these unequilibrated levels sometimes lead to inappropriate potassium repletion.

### Nutritional Status

Malnutrition is common in patients with ESRD receiving HD and the pathogenesis is complex. Underdialysis leads to anorexia and abnormalities in taste which impact dietary nutrition intake. Increasing dialysis adequacy offers a realistic prospect of improving nutritional intake. Some of the other factors involved ESRD-related malnutrition include the following:

- 1 Restrictions in diet and fluid which reduce the calories available and make food less attractive.
- 2 Medications that impair absorption of nutrients, bowel function, and/or appetite.
- 3 Loss of nutrients during HD.
- 4 Dialysis induced catabolism.
- 5 Chronic inflammation.

Poor nutrition reduces tissue repair and should be corrected to minimize the risk of wound infection or dehiscence. In the case of elective surgery, there should be adequate time to involve a dietician, increase dialysis adequacy, and improve nutritional intake prior to surgery. In cases where this is not possible via the enteral route, parenteral nutrition (TPN) can be used to supplement or replace oral intake and can be administered during dialysis sessions. Some patients whose taste and appetite are impaired despite optimal dialysis will tolerate nocturnal enteral feeding via a nasogastric tube.

### Hemodialysis Vascular Access

This is often described as the patient’s “lifeline.” The nephrologist will communicate with other involved clinicians to stress how the access should be maintained, cared for, and used and to discuss possible problems

associated with it. For example, if the patient has a known central venous stenosis, the anesthesiologist and surgeon should be informed as it may have implications for their practice or the planned procedure. As general rule, hemodialysis catheters should not be used for purposes other than dialysis (e.g., blood sample, central venous monitoring, and drug administration) except in an emergency. An Arterio-venous access may be at risk for thrombosis from procedure-associated hypotension. Access function should be checked as part of the postoperative evaluation.

### Issues Relating to Renal Transplantation

The first issue here relates to the “on-call” status of the patient awaiting transplant. In most cases, these patients will need to be suspended from the on-call list until they have recovered from their surgery. For some, the planned surgery will allow the patient to go on-call for the first time. The responsibility for coordinating this process lies with the nephrologist. A second issue relates to perioperative blood product administration. Transfused blood may cause an immunological response in the recipient, potentially making it more difficult for them to receive a renal transplant in the future. Nephrologists may ask for selected patient groups to receive human leukocyte antigen (HLA)-matched blood in attempt to reduce the risk of subsequent immunological issues. The availability of HLA matched blood will require close collaboration with the local blood transfusion service in advance of surgery. Patients who are on-call for transplant who receive blood transfusion perioperatively require follow-up blood sampling post-transfusion to assess antibody changes.

### Logistical Issues Relating to Perioperative Provision of Hemodialysis

The location and timing of dialysis need to be considered. The hospital where the surgery is to be performed may not have an on-site HD unit, or this unit may not be inside the main hospital building. In these scenarios, special arrangements will need to be made to provide HD when it is required. For example, in hospitals without chronic HD units, the patient may need to receive a period of renal replacement therapy in a critical care unit that offers this therapy for acute kidney injury patients until they are stable enough to transfer to a different site for intermittent HD. It is important to ensure that the patient’s fistula is properly maintained during this period of time. In most cases, it is preferred that dialysis is carried out on the day before surgery to minimize any risks from anticoagulation and from unresolved fluid or electrolyte shifts. Dialysis may also be needed in the immediate preoperative period if there is a particular problem with fluid or potassium control.

### Infection Control Issues

Patients with end-stage renal disease are at increased risk of bacterial colonization and infection by virtue of

altered neutrophil and monocyte function, impaired lymphocyte activation or number, cytokinemia and abnormal pathogen recognition (17). This risk naturally extends to organisms such as MRSA (methicillin-resistant *Staphylococcus aureus*) (18), VRE (vancomycin-resistant Enterococcus), and ESBL (extended-spectrum beta-lactamase-producing gram-negative organisms). Colonization or infection with these organisms may have implications for the location where the patient is nursed or receives their dialysis. It may also impact on the order of the operating list, which operating room is used and what surgical antimicrobial prophylaxis is required. It is therefore critical that information on infection status be communicated to the surgical and anesthetic teams involved and that clinicians appreciate the increased susceptibility of these patients to infection.

### Dialysis and Emergency Surgery

In some instances, it is not possible to undergo preoperative dialysis (as with a ruptured abdominal aortic aneurysm or for surgery to salvage a non-functional vascular access for HD). In these cases, medical management of hyperkalemia may be required with close intraoperative monitoring by the anesthesiologist and a plan to commence dialysis as soon postoperatively as is judged safe. Although HD patients running chronically elevated potassium levels may be less susceptible to hyperkalemia-induced cardiac toxicity than previously normokalemic patients (19), this cannot be guaranteed. It is also often assumed that preoperative fasting reduces the likelihood of hyperkalemia; it does not. The hormonal response to fasting favors the shift of potassium from the intracellular to the extracellular space.

### Reduction in Bleeding Risk

Patients with hemodialysis-dependent ESRD are at increased risk of perioperative bleeding. Chronic uremia (or more accurately the chronic presence of uremic toxins) is associated with (i) defective platelet granule release of serotonin and thromboxane A<sub>2</sub> (activation defect), (ii) reduced activity of platelet surface receptors (aggregation defect), and (iii) reduced von Willebrand factor activity (adhesion defect) (20,21). Anemia alters the normal pattern of flow in vessels, where red cells are predominantly found centrally and platelets are thrust outward toward the vessel wall.

Patients with end-stage renal disease may be taking medications such as aspirin and clopidogrel that reduce platelet aggregation. They will also be receiving prophylaxis against deep venous thrombosis (DVT) in the perioperative period, generally in the form of unfractionated heparin. Low molecular weight heparin, popular for DVT prophylaxis in Europe, undergoes predominantly renal excretion and accumulates in ESRD, increasing bleeding risk. If used, doses should be significantly reduced, and consideration given to monitoring of anti-Xa activity (22). Although low-dose aspirin has been safely continued through the perioperative period, clopidogrel should be discontinued 7 days prior to surgery unless there are specific indications for its use.

Adequate dialysis and uremia reduction in the perioperative period will help improve platelet function (heparin-free dialysis close to time of surgery). Administration of a 0.3 micrograms/kg dose of Desmopressin (dDAVP) releases factor VIII and von Willebrand factor from the endothelium (23), and this action lasts for between 4 and 12 hours. It should be noted that tachyphylaxis occurs. Factor replacement through administration of cryoprecipitate also shortens bleeding time in uremic patients, the effect lasting 12–24 hours. A positive effect of conjugated estrogen administration (0.6 mg/kg daily for 5 days) has also been found, commencing around 24 hours after the first doses and peaking after 5–7 days of therapy. In circumstances where other techniques have failed, tranexamic acid may be effective, although it accumulates in renal failure (21).

### Preoperative Anesthetic Assessment

In addition to the acquisition of basic patient data and clinical history, the key role of preoperative assessment is to identify correctable problems and institute therapy that optimizes the patient's organ function prior to the surgical and anesthetic challenge. The preoperative detection of cardiac ischemia risk is the most frequently discussed area. Scores such as the Revised Cardiac Risk Index (RCRI) (24) (Table 2) go some way toward identifying the higher risk patient. Traditional assessment of cardiac risk and ischemia has been the subject of several excellent reviews and guidelines (25,26) and will not be reviewed here. We would, however, like to highlight the potential utility of an integrated assessment of cardiopulmonary fitness in the detection of patients at higher risk of perioperative mortality or morbidity and briefly review the integrated preoperative CPET for functional status assessment.

#### Identifying Patients at Risk of Poor Outcomes – Functional Capacity and Oxygen Delivery

Major surgery is associated with endocrine changes and a systemic inflammatory response. The result of these changes is an increase in intraoperative, and especially postoperative, oxygen demand, and consumption. Ideally this demand is met through a rise in cardiac index and oxygen delivery and a parallel rise in oxygen extraction by the tissues (27).

**TABLE 2. Components of the revised cardiac risk index (24)**

Coronary artery disease
Heart failure
Cerebrovascular disease
Diabetes mellitus requiring insulin
Renal insufficiency (creatinine concentration > 176.8 $\mu\text{m}$ [ $> 2 \text{ mg/dl}$ ])
High-risk non-cardiac surgery (suprainguinal vascular, intrathoracic, or intraperitoneal procedures)

Each component receives one point if present, with scores of 2 or more representing intermediate to high risk of cardiac complications.

Oxygen delivery depends on cardiac output and the oxygen content of blood, with the dissolved oxygen contributing only a small fraction to the delivered oxygen. Thus, an adequate hemoglobin concentration and hemoglobin saturation level are important, but alterations in cardiac index have the greatest impact on oxygen delivery. For some patients, especially those with heart failure, the rise in delivery that should accompany the change in demand cannot be provided by their cardiopulmonary systems without pharmacological support and tissue hypoxia with metabolic failure ensues. Globally, this may be detected by a rise in lactate level, a worsening base deficit, or a fall in mixed venous or central venous oxygen saturation (normally 70–75%). It should be remembered that regional perfusion might be severely deranged before these global measures change. Derangements in global oxygen delivery have been associated with poor outcome after major surgery (28).

A critical part of perioperative management involves identifying these hypoperfusion-prone patients prior to surgery and intervening to optimize their cardiac status, oxygen delivery, and perfusion. Given the prevalence of cardiovascular disease in the HD-dependent ESRD population, these patients are very suitable targets for testing and investigation.

An increasingly utilized tool to evaluate functional capacity, oxygen demand, and delivery, is the integrated CPET, carried out using a stationary exercise bicycle or a treadmill. This test can provide valuable information on the causes of deficient oxygen delivery and the exercise level at which this occurs. The methodology for this investigation has been reviewed elsewhere (29), but a number of relevant parameters are measured, the most quoted being the peak oxygen uptake and the so-called anaerobic threshold (AT), the point at which oxygen delivery is insufficient to meet aerobic metabolic demands. Patients with an AT below 11 ml/minute/kg (or 11–14 ml/minute/kg with cardiac ischemia) are known to be at increased risk of poor postoperative outcomes after major non-cardiac surgery (30,31), and the test retains this discriminatory ability in the absence of cardiac risk factors.

These high-risk patients should have their care optimized in a high dependency or intensive care environment postoperatively (although some units admit such patients prior to surgery). It is important to differentiate CPET to assess functional capacity, oxygen delivery, oxygen consumption, and postoperative disposition from conventional stress testing to detect inducible cardiac ischemia. These investigations are not directly interchangeable, despite the ability of CPET to detect myocardial ischemia.

### Cardiovascular Dysfunction in the Hemodialysis Patient

Chronic kidney disease not only increases the risk of cardiovascular disease, it also worsens the associated outcomes (32,33). Cardiac mortality is between 10- and 20-fold greater for HD-dependent patients than matched controls that do not have CKD (34). The most

common cardiovascular issues in the patient with CKD are arteriosclerosis-mediated hypertension, ischemic heart disease, cerebrovascular disease, accelerated vascular and cardiac valvular calcification, impaired systolic and/or diastolic ventricular function (with concentric or eccentric left ventricular hypertrophy), and arrhythmogenic sudden cardiac death (35). The prevalence of these disorders increases with the severity of CKD, such that 32–34% of patients on dialysis for ESRD meet ECG or echocardiographic criteria for left ventricular hypertrophy (as do up to 80% of incident dialysis patients), 40% have symptomatic ischemic heart disease (and likely many more are asymptomatic), 40% have evidence of cardiac failure, and 32% have arrhythmia (36,37). These very likely place patients at higher risk of poor perioperative outcomes as has been shown for elderly patients with systolic ventricular dysfunction (symptomatic or asymptomatic) after vascular surgery (38).

The prevalence of heart failure continues to grow, as does the appreciation of the importance of heart failure with preserved ejection fraction, previously known as diastolic heart failure, which impacts adversely on ventricular filling and can lead to pulmonary edema at lower end-diastolic volumes (preload levels). Diastolic dysfunction is associated with increased risk of postoperative cardiovascular events and long-term cardiovascular mortality after vascular surgery (39).

### Hemodynamic Management of “High-Risk” Patients

High-risk patients may be defined as those with an AT < 11 ml/minute/kg, a RCRI Score  $\geq 3$  points, or a predicted perioperative mortality of > 5%. There are two main approaches to this patient group:

- 1 The use of additional (more invasive) monitoring such as central venous pressure (CVP), invasive arterial pressure, or less commonly pulmonary arterial catheterization. In addition to the standard targets identified above, this approach is usually based on achieving and maintaining a given CVP or pulmonary arterial wedge pressure (PAWP) as an index of adequate fluid loading, with pressor or inotropic agents used if this approach fails to meet MAP goals. There are significant limitations in assessing intravascular volume status through CVP or PAWP, given the poor relationship between CVP or PAWP and the patient's fluid responsiveness (40,41). Administration of anesthetic drugs in high-risk patients can be associated with a significant reduction in cardiac output and blood pressure, and the use of predominantly vasoconstrictor agents like metaraminol or phenylephrine in this setting transiently supports blood pressure but further diminishes cardiac output and risks reduction in tissue oxygenation. In the absence of cardiac output monitoring, this deficit may not be apparent to the anesthesiologist as mean arterial pressure targets have been met. If a

decision is made to monitor cardiac index, a baseline pre-anesthesia value is very important because simply achieving a rise from a postinduction nadir may not restore pre-anesthesia levels and adequate O<sub>2</sub> delivery.

- 2 The use of techniques focused on hemodynamic optimization or “goal-directed therapy,” specifically targeting defined cardiac function and oxygen delivery indices as well as maintaining a “safe” perfusion pressure. Intravenous fluids, inotropes, or vasopressors are used to achieve these end points, with increasing emphasis on goal-directed fluid therapy as core component (42). This model traditionally utilized the pulmonary artery catheter, but increasingly makes use of various additional monitors capable of assessing dynamic indices of vascular filling such as arterial waveform analysis to detect systolic pressure variation (SPV) or pulse pressure variation (PPV), which have better correlation with fluid responsiveness than the static indices of CVP and PAWP (43) (although the patient should be in sinus rhythm and mechanically ventilated). It is also possible to study the variation in the plethysmographic signal from a pulse oximeter to infer the presence and severity of SPV and guide fluid therapy (44,45). Information on cardiac function may be obtained less invasively through interrogation of aortic blood flow by esophageal Doppler techniques (46) or through arterial line-based pulse contour analysis and transpulmonary thermodilution, which also yields information on extravascular lung water levels and intrathoracic blood volume and global end-diastolic volume (preload) (47).

The literature on perioperative hemodynamic optimization generally focuses on maintaining normal or supranormal oxygen delivery indices through optimization of (i) intravascular volume and (ii) cardiac index. These techniques assume adequate arterial oxygenation and hemoglobin concentration. The literature on hemodynamic optimization continues to spark debate, but there are several positive studies and meta-analyses suggesting improved short-term outcomes, organ impairment, and potential for reduced hospital stay in major abdominal surgery including high-risk patients (48–52), and these techniques may help avoid over- or underhydration and the adverse effects that may result (53). There are, however, no studies focusing on perioperative hemodynamic optimization specifically in the ESRD population, and indeed these patients may be excluded from some trials. However, given the common cardiopulmonary comorbidities prevalent in the ESRD population, it is appropriate to consider such an approach in the patient with high-risk ESRD.

### Optimization in the Presence of Significant Active Cardiac Ischemia

Hemodynamic optimization of patients with severe or unstable ischemic heart disease requires an approach

that takes account of the fact that (i) their drug therapy often concentrates on beta-blockade and reduction in cardiac oxygen consumption and (ii) their major risk is critical cardiac ischemia or infarction. In these patients, optimization presupposes optimal cardiac revascularization and avoids or minimizes the use of beta-agonist inotropes. Fluid optimization is achievable using the tools discussed above. In the presence of ventricular dysfunction, cardiac output and oxygen delivery may be supported through the use of alternative inotropic agents such as phosphodiesterase inhibitors (e.g., milrinone) or the novel calcium-sensitizing inotrope, levosimendan (54), and perioperative support with an intra-aortic balloon pump may be of use in emergent cases where pump function is poor and revascularization not feasible. This approach has not yet been rigorously investigated and is unlikely to be a topic for a large randomized trial.

### Microvascular Resuscitation and Correction of Tissue Dysoxia

Chronic kidney disease is associated with endothelial dysfunction and microvascular perfusion abnormalities (55), related both to underlying comorbidities and specifically to CKD; these abnormalities are exaggerated during dialysis (56,57). Optimal perioperative management aims to maintain tissue perfusion and oxygenation and as such requires an optimized or recruited microvasculature. Tissue oxygenation in critical organs such as the brain can be measured. Cerebral oxygen saturation is monitored by near-infrared spectroscopy (58). Cerebral desaturation is associated with a higher risk of postoperative cognitive impairment (59,60) and may occur despite adequate mean arterial pressure and global hemodynamics, being induced, for example, by inadvertent hyperventilation and the cerebral vasoconstriction that accompanies it. This insult should be avoided, where possible, in the CKD population who are already at increased risk of vascular-origin cognitive impairment (61).

The technology to monitor absolute cerebral oxygen saturation is commercially available and is slowly emerging into non-cardiac perioperative and critical care. Given the position of the brain as the ultimate organ to be protected perioperatively, trials looking at the inclusion of cerebral saturation monitoring within optimization algorithms seem intuitive and desirable, but this area remains to be adequately investigated.

Most of the work carried out to date has involved macro-hemodynamics and been based on the assumption that targeting appropriate mean arterial pressure, cardiac output, and oxygen delivery necessarily equates to adequate tissue perfusion and oxygenation. In the context of relative anemia and hemodilution, two common perioperative issues in the ESRD patient with or without fluid optimization, it is useful to look to recent work on microvascular perfusion and functional capillary density to see whether there are additional factors that we need to consider when we attempt to optimize

tissue perfusion. This work has recognized (i) the critical role of blood viscosity in the maintenance of capillary density at tissue level – blood viscosity and shear stress act on the capillary endothelium and induce physiological nitric oxide (NO) release which increases capillary diameter and density (62) (ii) the detrimental impact of arteriolar vasoconstrictors, predominantly the alpha-agonists, which maintain mean arterial pressure but induce precapillary vasoconstriction and actually reduce functional capillary density and perfusion (63) and (iii) that the effect of reduced capillary density is further aggravated by tissue edema, which increases the capillary to cell diffusion distance.

Why is this relevant to the perioperative management of the patient with ESRD? We have already acknowledged the incidence of pre-existing microvascular impairment in CKD, so these patients are starting off with a deficit. There is also a prevalent approach based around “permissive anemia” in the perioperative period, patients with ESRD perhaps entering surgery with hemoglobin concentrations of 11–12 g/dl and encountering transfusion triggers of around 7 g/dl (in otherwise “well” individuals) to 8 or 9 g/dl (in the very elderly or patients with cardiovascular disease), extrapolated from the critical care environment, and we would like to stimulate research and discussion on the implications of this approach. Anemia, aggravated by hemodilution with crystalloids or low-viscosity colloids, reduces functional capillary density by failing to generate capillary NO release and so promoting vasoconstriction. An approach to transfusion based on detecting abnormal global measures of oxygenation such as lactate and mixed/central venous oxygen saturation may not be the most effective strategy, given that by the time these abnormalities occur, blood viscosity could already be low enough that capillary density has fallen.

There is, therefore, a balance to be sought between the beneficial effect of lower hematocrit on blood rheology and the detrimental effect of “viscosity failure” on perfusion. Indeed it has been suggested, based on animal studies of acute hemodilution and hemorrhage, that there may be an argument for a “viscosity trigger,” a point at which fluid (generally viscous colloids, hyperoncotic solutions, or blood) administration is required to recruit the microcirculation at hematocrit or hemoglobin levels that would not otherwise represent the conventional “transfusion trigger” (64,65). Thus, stored blood, although not immediately capable of full oxygen carriage, will improve tissue oxygenation through improvement in blood viscosity and functional capillary density (66). Similarly, tissue blood flow and oxygenation in severe anemia will be better maintained if blood viscosity is supported (67). This is a new concept that will require further clinical investigation, but which provides a tantalizing glimpse into the direction that optimization might take for populations including HD-dependent ESRD. At present, tools to monitor functional capillary density and capillary recruitment, such as sidestream dark-field imaging (68), are generally limited to clinical trials and not readily available to the practicing clinician.

### **Pulmonary Hypertension and Right Ventricular Dysfunction in the Hemodialysis Patient**

One of the most significant abnormalities in ESRD is pulmonary hypertension (PH), although this often receives much less clinical attention than it deserves. PH may be present as a result of cardiac dysfunction or have developed de novo after formation of an AV fistula and/or commencement of HD (69). The incidence of PH in patients with ESRD and AV fistulae may be as high as 40% (70).

The pathophysiology of PH in ESRD may be related to uremia-induced endothelial dysfunction, as basal NO levels have been shown to be lower in HD patients with PH compared to those without (71,72). This is thought to reduce the ability of the pulmonary vasculature to accommodate the increase in cardiac output derived from the AV fistula, and it has been suggested that PH should be specifically sought in patients scheduled for fistula formation, and the plan for fistula reconsidered in those who are identified as already having PH (73). Another factor that may account for the high frequency of PH in this population is pulmonary injury resulting from chronic exposure to microbubbles originating in the dialyzer or its tubing (74).

Pulmonary hypertension is an independent predictor of mortality in HD patients, with a 5-year survival rate of only 25% (69) compared to 39% for the overall HD population. It is interesting to note that both fistula closure and renal transplantation have been shown to reduce pulmonary artery pressures in HD patients with PH (71).

The presence of severe PH should be determined preoperatively as it will have a significant impact on the anesthetic management of the patient. Management goals should center on the avoidance of hypoxia, hypercapnia, acidosis, and hypothermia as each of these factors will increase pulmonary vascular resistance. Right ventricular preload must be maintained as right ventricular underfilling, through ventricular interdependence, will lead to septal shift and a reduction in left ventricular preload which will lead in turn to a reduction in cardiac output and hypotension/ischemia (75).

### **General Aspects of Intra-Operative Management**

Aside from the impact of surgery and comorbidity, there are a number of general perioperative care issues to be considered in this patient population. Intravenous access and blood pressure monitoring should avoid the AV fistula arm. Patient identification armbands must not encroach on the fistula, and compression of the fistula during surgery must not occur (76). In cases requiring central venous access, the subclavian approach has been associated with an increase in the rate of subclavian vein stenosis (77). This may become sufficiently severe as to prevent both the future use of the subclavian vein as well as the successful placement of an AV access in the

ipsilateral arm (because of inadequate venous drainage resulting in marked arm swelling). Thus, it has been recommended that subclavian central venous access should be avoided. There are those who argue that improvements in central venous catheter technology and care, use of ultrasound guided insertion, and a reduction in central venous catheter-associated infection may result in a lower risk of stenosis, although this remains to be studied.

### Pharmacological Issues and Drug Choices

Potential alterations in volume of distribution, protein binding, drug metabolism, and excretion must be considered carefully before deciding upon a particular anesthetic technique.

### Anesthetic Drugs

Propofol is an intravenous induction agent, which can also be administered by continuous infusion to maintain anesthesia or sedation. The pharmacokinetics of bolus administration, and of maintenance infusion, do not seem to be markedly altered in patients with ESRD (including those dialyzed 12 hours prior to surgery) (78,79).

Sevoflurane is a widely used inhalational anesthetic agent that may react with carbon dioxide absorbents to produce a substance called Compound A, which is nephrotoxic in rat models (80). Although Sevoflurane is also biotransformed to release potentially nephrotoxic inorganic fluoride ions, it has been used in renal disease and dialysis-dependent ESRD patients and it appears to be safe, with serum inorganic fluoride levels and elimination rate no different than healthy controls (81,82).

Patients with end-stage renal failure have below normal levels of plasma cholinesterase. This results in a prolongation of action of the depolarizing muscle relaxant suxamethonium (83) and the non-depolarizing relaxant mivacurium (84). A significant hyperkalemic response to suxamethonium is not observed in chronic renal failure provided the preoperative potassium level is within normal limits (85).

The non-depolarizing muscle relaxant drug atracurium and the stereoisomer cis-atracurium undergo a process called Hofmann elimination which is independent of renal and hepatic function, making these agents useful neuromuscular blockers for the renal failure patient (86). In contrast, the clinical effects of the amino-steroid muscle relaxant drugs vecuronium and rocuronium are significantly prolonged in renal failure because of reduced clearance, the disease process causing ESRD, or the effects of other medications (87–89).

Sugammadex is a novel cyclodextrin that has been demonstrated to rapidly reverse neuromuscular blockade induced by rocuronium and vecuronium, even at depths of block where conventional reversal with acetylcholinesterase inhibitors would be ineffective (90). The resulting Sugammadex–rocuronium complex is excreted via the kidney, although clearance is obviously reduced (91). In a recent study of patients with renal failure,

Sugammadex (2 mg/kg) rapidly reversed the neuromuscular blockade induced by rocuronium without any adverse effects (92); 10 of the 15 patients with renal failure in this study were undergoing dialysis. There is clearly a need for further studies of this novel reversal agent in much greater numbers of patients with renal failure to clarify its role in this setting.

### Opioid Analgesics

When considering perioperative analgesic requirements for HD patients, it is important to recognize the effect of renal failure both on the clearance of both parent drug and its metabolites, e.g., morphine and morphine-3-glucuronide, and morphine-6-glucuronide. The impact of CKD and ESRD on common opioid agents and considerations for use are outlined in Table 3. The mechanics of dialysis will also play an important role in deciding which opioid, if any, to utilize (93).

With its unique mode of metabolism by plasma non-specific esterases, intra-operative analgesia and prevention of hemodynamic responses in patients with dialysis-dependent ESRD may be safely and reliably provided through infusion of remifentanyl, a potent  $\mu$  receptor agonist with a constant context-sensitive half-time, i.e., no effect site accumulation and a predictable offset of action which is independent of infusion duration, with no apparent increase in adverse effects (94,95). Although end-stage renal failure prolongs the elimination half-life and reduces the central clearance of remifentanyl, the clinical significance of these findings appears to be minimal (96). Naturally, intraoperative use of such an agent requires additional techniques to provide postoperative analgesia.

### Non-Steroidal Anti-Inflammatory Agents (NSAIDs)

Non-steroidal anti-inflammatory agents are often used in hemodialysis patients either to reduce cardiovascular risk (in the case of aspirin) or to help control chronic pain. A recent retrospective observational cohort study (97) randomly selected over 28,000 hemodialysis patients from The Dialysis Outcomes and Practice Patterns Study (DOPPS) to analyze aspirin prescription and outcomes. They found that aspirin prescription was not associated with an increased risk of gastrointestinal hemorrhage in these patients. This point has been debated (98) with calls for adequately powered prospective trials to clarify the risk of gastrointestinal hemorrhage in hemodialysis patients taking NSAIDs. Also of concern is the potential adverse effect of these agents on residual renal function, a risk that has not been well evaluated. A careful risk/benefit decision needs to be taken on an individual patient basis before deciding to prescribe NSAIDs to this patient group during and after surgery.

### Use of Regional and Neuraxial Anesthesia and Analgesia

Regional anesthetic techniques have been used to aid creation of arteriovenous fistulae (99). In chronic renal



TABLE 3. Characteristics of opioids and their metabolites in renal failure and dialysis

Opioid	Metabolism	Metabolites (IA) = inactive (A) = active		Excretion	Accumulation in renal failure	Removed by HD	Safety profile in HD patient
		(IA) = inactive	(A) = active				
Morphine	Hepatic	Normorphine (IA)	Morphine-3-glucuronide, (IA)	Renal	Yes	Yes	Reduce dose and increase interval. Extreme caution required
Fentanyl	Hepatic	Morphine-6-glucuronide (A)	Norfentanyl (IA)	Renal (7% unchanged)	Parent compound may accumulate	No	Safe – reduce dose
Alfentanil	Hepatic	Noralfentanil (IA)		Renal	No	No	Safe – reduce dose because of increased free fraction
Remifentanyl	Blood & tissue esterases	GR90291 (IA)		Renal	No	No	Safe
Codaine	Hepatic with polymorphism	Codaine-6-glucuronide (A)		Renal	Yes	Limited data	Avoid – serious adverse effects have been reported
		Norcodeine (IA)					
		Morphine (A)					
		Normorphine (IA)					
		Morphine-3-glucuronide, (IA)					
		Morphine-6-glucuronide (A)					
Oxycodone	Hepatic with polymorphism	Noroxycodone (IA)		Renal	Yes	No data	Ideally avoid. If used, reduce dose and increase interval. Extreme caution required
		Oxymorphone (A)					
		Conjugated oxymorphone (IA)					
Tramadol	Hepatic	O-dimethyl-tramadol (A)		Renal	Yes	Yes	Avoid – lowered seizure threshold and altered mental status
Meperidine	Hepatic	Normeperidine (A)		Renal (5% unchanged)	Normeperidine accumulates	No (normeperidine)	Avoid – metabolite accumulation causes seizures
		Normeperidinic acid					
		Meperidinic acid					
Methadone	Hepatic			Renal and fecal	–	No	Appears safe
Hydromorphone	Hepatic	Hydromorphone-3-glucuronide (neuro-excitation)		Renal	Yes	Yes	Neuro-excitation possible. Use lower dose or longer interval. If used, additional dose may be needed after HD

HD, hemodialysis.

failure patients with low bicarbonate values, the onset of action of local anesthetics may be delayed (100) and the duration of effect may be lower in these patients perhaps owing to low protein binding (101). Epidural analgesia has been successfully utilized for labor analgesia and cesarean delivery in the setting of end-stage renal failure (101) and for renal transplantation (102) and provides safe and effective postoperative analgesia after abdominal and thoracic surgery. Platelet number/function and coagulation profile should be checked before any regional technique is carried out in these patients, and drugs such as clopidogrel should have been stopped sufficiently in advance.

Bilateral transversus abdominis plane (TAP) blocks are used with increasing frequency to minimize opioid usage following abdominal surgery. They have been used as part of a balanced analgesic regime in patients undergoing renal transplantation. In a pilot study involving 20 patients, TAP blocks were shown to reduce both intra- and postoperative opioid consumption (103). Paravertebral block may be used to provide analgesia after thoracotomy or unilateral abdominal procedures such as nephrectomy.

### Intravenous Fluids

Careful consideration should be given to the type and quantity of fluid to be administered during surgery. This will be determined by the preoperative hydration status of the patient, duration of surgery, and the estimated fluid losses occurring during surgery, along with dynamic preload measures if utilized. Overzealous administration of intravenous fluid risks tissue and pulmonary edema (remembering that diastolic dysfunction is prevalent), while under administration risks hemodynamic instability and impairment of oxygen delivery. Large volumes of 0.9% saline solution may lead to hypernatremia and a significant hyperchloremic acidosis, although this can be corrected by dialysis. Solutions such as Hartmann's solutions (Ringer's) contain less sodium and less chloride, but some advocate avoidance because they contain some potassium. There is a wide range of colloid fluids on the market now, broadly breaking down into dextrans, gelatins, and (heta) starches. Lower molecular weight starches have been shown to reduce the incidence of delayed graft function after renal transplantation compared to higher molecular weight versions (104) and are increasingly used as first-line colloids.

### Postoperative Care

Whether to admit the patient to a high dependency or intensive care unit postoperatively will depend on the nature of the surgery and specific patient factors (determined at preoperative assessment) that may place them at higher risk of cardiorespiratory complications. Hemodialysis should ideally be delayed until the risk of fluid shifts, and hemorrhage has fallen (some suggest at least 24 hours postoperatively) (76), and depending on the

nature of surgery, anticoagulation may need to be reduced or omitted. The re-establishment of postoperative dialysis will require close liaison with a nephrologist and a specific plan for this should be in place preoperatively.

The immediate postoperative period will require close attention to fluid and electrolyte balance. As with intraoperative fluids, we tend to give a low background maintenance fluid infusion (taking into account native urine output and insensible losses) supplemented by bolus doses of crystalloid or colloid to maintain hemodynamic stability and help reduce the likelihood of fluid overload. Electrolyte, urea, and creatinine levels should be checked in the early postoperative period and as indicated thereafter.

A multimodal approach to postoperative analgesia should be employed. If the patient suffers from chronic pain, he/she will have a higher analgesic requirement and should receive his/her usual analgesics supplemented by additional methods (e.g., regional technique) to cover for the acute surgical insult. In Europe, intravenous preparations of paracetamol are effective and beneficial in patients whose gastrointestinal function has not recovered. Combinations of local anesthetics wound infiltration, nerve blocks, or regional analgesia where the surgery is amenable to these, and regular paracetamol markedly diminish opioid requirements, which is a significant aim given the risk of accumulation of drug or metabolites. If a clinician determines that it is necessary to administer opioids such as morphine, the dose should be reduced and the patient should be carefully monitored. The use of intrathecal or single-shot epidural opioids provides good quality analgesia for up to 24 hours postoperatively, although there is little evidence on this approach in the ESRD population. Such patients are routinely monitored for respiratory depression even in the absence of organ impairment.

With regard to management of hypertension, ischemic heart disease, and heart failure, the aim should be to re-establish the patient on his/her normal medications as soon as is feasible in the postoperative period. This will be dictated somewhat by gastrointestinal function and any hemodynamic upset that may have occurred in the perioperative period. For abdominal surgery patients, placing a Salem sump or fine-bore feeding tube distal to the pylorus at the time of surgery will facilitate enteral drug administration even in the presence of reduced gastric emptying.

### Conclusion

Dialysis-dependent ESRD is a complex and increasing healthcare problem. The frequency with which these patients present for elective or emergency surgery is appreciable. The presence of severe comorbidities and potential for clotting, fluid, electrolyte, and drug handling abnormalities in the perioperative period provides a challenge for all healthcare professionals involved in their care. Traditional approaches to recognition and management of high-risk patients are evolving as a result of research highlighting the potential for new tools to

assist with preoperative diagnosis of functional compromise, optimization of hemodynamic and tissue oxygenation, and understanding of microvascular dynamics. With careful planning, appropriate preoperative investigation, and attention to detail in the perioperative period, the probability of good patient outcomes can be maximized.

## References

1. U.S. Renal Data System: *USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government
2. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. *Nephrol Dial Transplant* 9:1136–1142, 1994
3. Mathew A, Devereaux PJ, O'Hare A, Tonelli M, Thiesens-Philbrook H, Nevis IF, Iansavichus AV, Garg AX: Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis. *Kidney Int* 73:1069–1081, 2008
4. Ansell D, Feehally J, Fogarty D, Inward C, Tomson CR, Warwick G, Williams A: UK Renal Registry 2009 12th Annual Report of the Renal Association. *Nephron Clin Pract* 115(Suppl. 1), 2010. The data reported here have supplied by the UK Renal Registry of the Renal Association. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as official policy or interpretation of the UK Renal Registry or the Renal Association.
5. Hemodialysis Adequacy 2006 Work Group: Clinical practice guidelines for hemodialysis adequacy, update 2006. *Am J Kidney Dis* 48(Suppl. 1):S2–S90, 2006
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 355:2085–2098, 2006
7. KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. *Am J Kidney Dis* 50:471–530, 2007
8. Singh AK: What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? *Curr Opin Nephrol Hypertens* 19:420–424, 2010
9. Peralta CA, Shlipak MG, Wassel-Fyr C, Bosworth H, Hoffman B, Martins S, Oddone E, Goldstein MK: Association of antihypertensive therapy and diastolic hypotension in chronic kidney disease. *Hypertension* 50:474–480, 2007
10. Sheehy AM, Gabbay RA: An overview of preoperative glucose evaluation, management, and perioperative impact. *J Diabetes Sci Technol* 3:1261–1269, 2009
11. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE, American Association of Clinical Endocrinologists, American Diabetes Association: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Endocr Pract* 15:353–369, 2009
12. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ: Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 360:1283–1297, 2009
13. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. *Nephrol Dial Transplant* 24:1506–1523, 2009
14. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG: K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? *Int Urol Nephrol* 38:739–743, 2006
15. Li S, Chen YW, Peng Y, Foley RN, St Peter WL: Trends in Parathyroidectomy Rates in US Hemodialysis Patients From 1992 to 2007. *Am J Kidney Dis* 2010. DOI: 10.1053/j.ajkd.2010.10.041
16. Cruz DN, Perazella MA: Biochemical aberrations in a dialysis patient following parathyroidectomy. *Am J Kidney Dis* 29:759–762, 1997
17. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Traanaes A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. *Clin J Am Soc Nephrol* 3:1526–1533, 2008
18. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD: Prevalence of colonization with community-associated methicillin-resistant *Staphylococcus aureus* among end-stage renal disease patients and healthcare workers. *Infect Control Hosp Epidemiol* 30:4–8, 2009
19. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med* 169:1156–1162, 2009
20. Heras MH, Hernandez RS, Fernandez-Reyes MJ, Diez AI: [Management of perioperative bleeding in the renal patient]. *Nefrologia* 28:593–596, 2008
21. Galbusera M, Remuzzi G, Boccardo P: Treatment of bleeding in dialysis patients. *Semin Dial* 22:279–286, 2009
22. Gallieni M, Cozzolino M, Ronga C, Brancaccio D: Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. *Nat Clin Pract Nephrol* 4:488–489, 2008
23. Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB: Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. *Nephron Clin Pract* 114:c248–c252, 2010
24. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L: Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 100:1043–1049, 1999
25. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, ACC/AHA Task Force Members, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Md RN, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation* 116:1971–1996, 2007
26. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Lung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Bergh G, Vermassen F, Hoeks SE, Vanhorebeek I, ESC Committee for Practice Guidelines (CPG): Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA). *Eur Heart J* 30:2769–2812, 2009
27. Nichols D, Nielsen ND: Oxygen delivery and consumption: a macrocirculatory perspective. *Crit Care Clin* 26:239–253, 2010
28. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED: Changes in central venous saturation after major surgery, and association with outcome. *Crit Care* 9:R694–R699, 2005
29. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV, American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Interdisciplinary Council on Quality of Care and Outcomes Research: Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation* 122:191–225, 2010
30. Ridgway ZA, Howell SJ: Cardiopulmonary exercise testing: a review of methods and applications in surgical patients. *Eur J Anaesthesiol* 27:858–865, 2010
31. Wilson RJ, Davies S, Yates D, Redman J, Stone M: Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery. *Br J Anaesth* 105:297–303, 2010
32. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 375:2073–2081, 2010
33. Di Angelantonio E, Chowdhury R, Sarwar N, Asplund T, Danesh J, Gudnason V: Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. *BMJ* 341:c4986, 2010
34. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 15:1307–1315, 2004
35. Miller L, Sood M, Sood A, Reslerova M, Komenda P, Rigatto C, Bueti J: Anonymous Anonymous Anonymous Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. *Int Urol Nephrol* 42:1007–1014, 2010

36. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group: Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int* 65:2380–2389, 2004
37. Shastri S, Sarnak MJ: Cardiovascular disease and CKD: core curriculum 2010. *Am J Kidney Dis* 56:399–417, 2010
38. Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, Elhendy A, Verhagen HJ, Thomson IR, Bax JJ, Fleisher LA, Poldermans D: Prognostic implications of asymptomatic left ventricular dysfunction in patients undergoing vascular surgery. *Anesthesiology* 112:1316–1324, 2010
39. Matyal R, Hess PE, Subramaniam B, Mitchell J, Panzica PJ, Pomposelli F, Mahmood F: Perioperative diastolic dysfunction during vascular surgery and its association with postoperative outcome. *J Vasc Surg* 50:70–76, 2009
40. Marik PE, Baram M, Vahid B: Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. *Chest* 134:172–178, 2008
41. Osman D, Ridel C, Ray P, Monnet X, Anguel N, Richard C, Teboul JL: Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. *Crit Care Med* 35:64–68, 2007
42. Davies SJ, Yates D, Wilson RJ: Dopexamine has no additional benefit in high-risk patients receiving goal-directed fluid therapy undergoing major abdominal surgery. *Anesth Analg* 112:130–138, 2011
43. Marik PE, Cavallazzi R, Vasu T, Hirani A: Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med* 37:2642–2647, 2009
44. Loupec T, Nanadoumgar H, Frasca D, Petitpas F, Laksiri L, Baudouin D, Debaene B, Dahyot-Fizelier C, Mimoz O: Pleth variability index predicts fluid responsiveness in critically ill patients. *Crit Care Med* 39:294–299, 2011
45. Forget P, Lois F, de Kock M: Goal-directed fluid management based on the pulse oximeter-derived pleth variability index reduces lactate levels and improves fluid management. *Anesth Analg* 111:910–914, 2010
46. Phan TD, Ismail H, Heriot AG, Ho KM: Improving perioperative outcomes: fluid optimization with the esophageal Doppler monitor, a meta-analysis and review. *J Am Coll Surg* 207:935–941, 2008
47. Benington S, Ferris P, Nirmalan M: Emerging trends in minimally invasive haemodynamic monitoring and optimization of fluid therapy. *Eur J Anaesthesiol* 26:893–905, 2009
48. Abbas SM, Hill AG: Systematic review of the literature for the use of oesophageal Doppler monitor for fluid replacement in major abdominal surgery. *Anaesthesia* 63:44–51, 2008
49. Giglio MT, Marucci M, Testini M, Brienza N: Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. *Br J Anaesth* 103:637–646, 2009
50. Mayer J, Boldt J, Mengistu AM, Rohm KD, Suttner S: Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: a randomized, controlled trial. *Crit Care* 14:R118, 2010
51. Brienza N, Giglio MT, Marucci M, Fiore T: Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. *Crit Care Med* 37:2079–2090, 2009
52. Benes J, Chytra I, Altmann P, Hluchy M, Kasal E, Svitak R, Pradl R, Stepan M: Intraoperative fluid optimization using stroke volume variation in high risk surgical patients: results of prospective randomized study. *Crit Care* 14:R118, 2010
53. Futier E, Constantin JM, Petit A, Chanques G, Kwiatkowski F, Flamein R, Slim K, Sapin V, Jaber S, Bazin JE: Conservative vs restrictive individualized goal-directed fluid replacement strategy in major abdominal surgery: a prospective randomized trial. *Arch Surg* 145:1193–1200, 2010
54. Milligan DJ, Fields AM: Levosimendan: calcium sensitizer and inodilator. *Anesthesiol Clin* 28:753–760, 2010
55. Wu-Wong JR: Endothelial dysfunction and chronic kidney disease: treatment options. *Curr Opin Investig Drugs* 9:970–982, 2008
56. Santesson P, Danielsson A, Iseda I, Adamson U, Lins PE, Jorneskog G: Impaired peripheral micro- and macrocirculation during hemodialysis in uremic patients. *Int Angiol* 29:362–370, 2010
57. Bemelmans RH, Boerma EC, Barendregt J, Ince C, Rommes JH, Spronk PE: Changes in the volume status of haemodialysis patients are reflected in sublingual microvascular perfusion. *Nephrol Dial Transplant* 24:3487–3492, 2009
58. Murkin JM, Arango M: Near-infrared spectroscopy as an index of brain and tissue oxygenation. *Br J Anaesth* 103(Suppl. 1):i3–i13, 2009
59. Casati A, Fanelli G, Pietropaoli P, Proietti R, Tufano R, Danelli G, Fierro G, De Cosmo G, Servillo G: Continuous monitoring of cerebral oxygen saturation in elderly patients undergoing major abdominal surgery minimizes brain exposure to potential hypoxia. *Anesth Analg* 101:740–747, 2005
60. de Tournay-Jette E, Dupuis G, Bherer L, Deschamps A, Cartier R, Denault A: The relationship between cerebral oxygen saturation changes and post-operative cognitive dysfunction in elderly patients after coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 25:95–104, 2011
61. Arismendi-Morillo G, Fernandez-Abreu M: Ultrastructural cutaneous microvascular pathology of young adults aged up to 50 years with chronic kidney disease and vascular cognitive impairment. *Ultrastruct Pathol* 34:214–218, 2010
62. Tsai AG, Acero C, Nance PR, Cabrales P, Frangos JA, Buerk DG, Intaglietta M: Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. *Am J Physiol Heart Circ Physiol* 288:H1730–H1739, 2005
63. Maier S, Hasibeder WR, Hengl C, Pajk W, Schwarz B, Margreiter J, Ulmer H, Engl J, Knotzer H: Effects of phenylephrine on the sublingual microcirculation during cardiopulmonary bypass. *Br J Anaesth* 102:485–491, 2009
64. Salazar Vazquez BY, Martini J, Chavez Negrete A, Cabrales P, Tsai AG, Intaglietta M: Microvascular benefits of increasing plasma viscosity and maintaining blood viscosity: counterintuitive experimental findings. *Biorheology* 46:167–179, 2009
65. Tsai AG, Hofmann A, Cabrales P, Intaglietta M: Perfusion vs. oxygen delivery in transfusion with “fresh” and “old” red blood cells: the experimental evidence. *Transfus Apher Sci* 43:69–78, 2010
66. Cabrales P, Martini J, Intaglietta M, Tsai AG: Blood viscosity maintains microvascular conditions during normovolemic anemia independent of blood oxygen-carrying capacity. *Am J Physiol Heart Circ Physiol* 291:H581–H590, 2006
67. Cabrales P, Intaglietta M, Tsai AG: Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. *Shock* 23:549–555, 2005
68. Goedhart PT, Khalilzada M, Bezemer R, Merza J, Ince C: Sidestream Dark Field (SDF) imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the microcirculation. *Opt Express* 15:15101–15114, 2007
69. Yigla M, Fruchter O, Aharonson D, Yanay N, Reisner SA, Lewin M, Nakhoul F: Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. *Kidney Int* 75:969–975, 2009
70. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, Reisner SA: Pulmonary hypertension in patients with end-stage renal disease. *Chest* 123:1577–1582, 2003
71. Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. *Nephrol Dial Transplant* 20:1686–1692, 2005
72. Yigla M, Abassi Z, Reisner SA, Nakhoul F: Pulmonary hypertension in hemodialysis patients: an unrecognized threat. *Semin Dial* 19:353–357, 2006
73. Yigla M, Banderski R, Azzam ZS, Reisner SA, Nakhoul F: Arterio-venous access in end-stage renal disease patients and pulmonary hypertension. *Ther Adv Respir Dis* 2:49–53, 2008
74. Barak M, Nakhoul F, Katz Y: Pathophysiology and clinical implications of microbubbles during hemodialysis. *Semin Dial* 21:232–238, 2008
75. Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ: Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. *Crit Care* 14:R169, 2010
76. Palevsky PM: Perioperative management of patients with chronic kidney disease or ESRD. *Best Pract Res Clin Anaesthesiol* 18:129–144, 2004
77. Cimochoowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H: Superiority of the internal jugular over the subclavian access for temporary dialysis. *Nephron* 54:154–161, 1990
78. Kirvela M, Olkkola KT, Rosenberg PH, Yli-Hankala A, Salmela K, Lindgren L: Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in ureaemic patients. *Br J Anaesth* 68:178–182, 1992
79. Ickx B, Cockshott ID, Barvais L, Byttebier G, De Pauw L, Vandesteene A, D’Hollander AA: Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. *Br J Anaesth* 81:854–860, 1998
80. Gonsowski CT, Laster MJ, Eger EI 2nd, Ferrell LD, Kerschmann RL: Toxicity of compound A in rats. Effect of increasing duration of administration. *Anesthesiology* 80:566–573, 1994
81. Mazze RI, Callan CM, Galvez ST, Delgado-Herrera L, Mayer DB: The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: a retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. *Anesth Analg* 90:683–688, 2000
82. Nishiyama T, Aibiki M, Hanaoka K: Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis. *Anesth Analg* 83:574–577, 1996
83. Ryan DW: Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant. *Br J Anaesth* 49:945–949, 1977
84. Phillips BJ, Hunter JM: Use of mivacurium chloride by constant infusion in the anephric patient. *Br J Anaesth* 68:492–498, 1992
85. Thapa S, Brull SJ: Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. *Anesth Analg* 91:237–241, 2000
86. Boyd AH, Eastwood NB, Parker CJ, Hunter JM: Pharmacodynamics of the 1R cis-1’R cis isomer of atracurium (51W89) in health and chronic renal failure. *Br J Anaesth* 74:400–404, 1995
87. Lynam DP, Cronnelly R, Castagnoli KP, Canfell PC, Caldwell J, Arden J, Miller RD: The pharmacodynamics and pharmacokinetics of vecuronium

- in patients anesthetized with isoflurane with normal renal function or with renal failure. *Anesthesiology* 69:227–231, 1988
88. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT: Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. *Br J Anaesth* 71:222–226, 1993
  89. Robertson EN, Driessen JJ, Booij LH: Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. *Eur J Anaesthesiol* 22:4–10, 2005
  90. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J: Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. *Anesthesiology* 104:667–674, 2006
  91. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM: Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. *Br J Anaesth* 104:31–39, 2010
  92. Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM: Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. *Br J Anaesth* 101:492–497, 2008
  93. Dean M: Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 28:497–504, 2004
  94. Westmoreland CL, Hoke JF, Sebel PS, Hug CCJ, Muir KT: Pharmacokinetics of remifentanyl (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. *Anesthesiology* 79:893–903, 1993
  95. Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P, Albrecht S, Shaikh S: Offset of pharmacodynamic effects and safety of remifentanyl in intensive care unit patients with various degrees of renal impairment. *Crit Care* 8:R21–R30, 2004
  96. Dahaba AA, Oetl K, von Klobucar F, Reibnegger G, List WF: End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanyl. *Can J Anaesth* 49:369–374, 2002
  97. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW: Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 50:602–611, 2007
  98. Tseng GY, Lin HJ: Aspirin prescription and outcomes in hemodialysis patients. *Am J Kidney Dis* 51:1070–1071, 2008
  99. Misiolek HD, Kucia HJ, Knapik P, Werszner MM, Karpe JW, Gumprecht J: Brachial plexus block with ropivacaine and bupivacaine for the formation of arteriovenous fistula in patients with end-stage renal failure. *Eur J Anaesthesiol* 22:473–475, 2005
  100. Al-mustafa MM, Massad I, Alsmady M, Al-qudah A, Alghanem S: The effect of low serum bicarbonate values on the onset of action of local anesthesia with vertical infraclavicular brachial plexus block in patients with end-stage renal failure. *Saudi J Kidney Dis Transpl* 21:494–500, 2010
  101. Dhir S, Fuller J: Case report: pregnancy in hemodialysis-dependent end-stage renal disease: anesthetic considerations. *Can J Anaesth* 54:556–560, 2007
  102. Hadimioglu N, Ertug Z, Bigat Z, Yilmaz M, Yegin A: A randomized study comparing combined spinal epidural or general anesthesia for renal transplant surgery. *Transplant Proc* 37:2020–2022, 2005
  103. Mukhtar K, Khattak I: Transversus abdominis plane block for renal transplant recipients. *Br J Anaesth* 104:663–664, 2010
  104. Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C: Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. *Br J Anaesth* 100:504–508, 2008